Abstract:Sulfasalazine needs frequent daily dosing and the administration of numerous tablets per day pose challenges to patient compliance, contributing to increased adverse effects and difficulties in disease control. These inconveniences result in less effective treatment for arthritis associated with inflammatory bowel disease i.e. ulcerative colitis etc. To improve drug bioavailability, a delayed-release mechanism that releases the drug at the colon is necessary. To develop and optimise colon-targeted controlled release bilayer tablets coated with pH-dependent polymers. The bilayer tablets containing the immediate release part and sustained release part were developed. The tablets were coated with enteric-coated with Eudragit® S-100 and L-100 to achieve release in the colon. Granule properties and tablets were evaluated. The physicochemical parameters of the tablets were evaluated including, stability study, and drug release in 0.1 N HCl (pH 1.2), pH 6.8 phosphate buffer, pH 7.4 phosphate buffer for 2, 1, and up to 24 hours respectively. Radiographic imaging and in vivo pharmacokinetic studies were also done in Rabbits. The bilayer tablets containing immediate and sustained release were successfully developed for the colon targeting. The granule properties were found within the acceptable range indicating good flow properties. The physicochemical properties of the tablets were also found acceptable. The tablets did not show release in 0.1 N HCl and 6.8 phosphate buffer but drug release was found under control in the 7.4 pH buffer. Sulfasalazine coated bilayer tablets were found stable and no significant changes were observed in the stability studies. Based on the X-ray studies, the formulated tablet remained discernible in the stomach, small intestine, and colon for a duration of up to 24 hours. Finally, by the 32nd hour, the tablet was no longer visible in the X-ray examination, leading to the conclusion of complete drug release. The drug concentration in plasma remained within the therapeutic range for up to 24 hours in vivo . These novel formulations present substantial advantages, providing prolonged targeted drug release and reducing systemic adverse effects. The results suggest promising potential for treating arthritis in Inflammatory bowel disease (IBD) patients, offering a solution to current delivery systems.

Colon-targeted 3D-Printed mesalamine tablets: Core-shell design and in vitro/ex-vivo evaluation

Formulation, Characterization and In Vitro Evaluation of Mesalamine and Bifidobacterium bifidum Loaded Hydrogel Beads in Capsule System for Colon Targeted Delivery

Lipid-polymer nano core-shell type hybrid system for colon specific drug delivery

Multi-effect formulation based on pH-Responsive psyllium Mucilage/Poly(vinyl alcohol) nanofibers for controlled delivery of mesalamine

Development of Polymeric-Based Formulation as Potential Smart Colonic Drug Delivery System

Enrichment of aqueous solubility and dissolution profile of mesalamine: In vitro evaluation of solid dispersion

Formulation and development of novel Sulfasalazine bilayer tablets for the treatment of arthritis associated with IBD: In-vitro and In-vivo Investigations

Formulation, Evaluation and Comparison of Mesalamine compression coated tablets by using Natural and Semi synthetic polymers

Fabricating a Shell-Core Delayed Release Tablet Using Dual FDM 3D Printing for Patient-Centred Therapy

Development of 3D-Printed Bicompartmental Devices by Dual-Nozzle Fused Deposition Modeling (FDM) for Colon-Specific Drug Delivery

3D printed tacrolimus suppositories for the treatment of ulcerative colitis

Film Coating of Phosphorylated Mandua Starch on Matrix Tablets for pH-Sensitive Release of Mesalamine

Design of colon-targeted drug delivery of dexamethasone: Formulation and in vitro characterization of solid dispersions

Advancements in Colon-Targeted Drug Delivery: A Comprehensive Review on Recent Techniques with Emphasis on Hot-Melt Extrusion and 3D Printing Technologies

A core-shell multi-drug platform to improve gastrointestinal tract microbial health using 3D printing

3D‐Printed Lipid Mesophases for the Treatment of Chronic Liver Disease

A Novel Mesalamine Loaded Hybrid Nanoparticle-in-Microparticle for Colon Targeting: In-vitro and In-vivo Investigations

The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome

Colon-targeted delivery of niclosamide from solid dispersion employing a pH-dependent polymer via hotmelt extrusion for the treatment of ulcerative colitis in mice

Film Coatings Based on Aqueous Shellac Ammonium Salt "Swanlac® ASL 10" and Inulin for Colon Targeting

Development of a chitosan based double layer-coated tablet as a platform for colon-specific drug delivery